2024-03-29T11:49:21Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/52142023-07-06T10:11:45Zcom_20.500.12105_2145com_20.500.12105_2051com_20.500.12105_2144col_20.500.12105_2146
Repisalud
author
Bell, Robert M.
author
Botker, H. E.
author
Carr, R. D.
author
Davidson, S. M.
author
Downey, J. M.
author
Dutka, D. P.
author
Heusch, G.
author
Ibáñez, Borja
author
Macallister, R.
author
Stoppe, C.
author
Ovize, M.
author
Redington, A.
author
Walker, J. M.
author
Yellon, D. M.
funder
British Health Foundation
funder
Medical Research Council (Reino Unido)
2017-10-30T13:15:41Z
2017-10-30T13:15:41Z
2016
Basic Res Cardiol. 2016; 111(4):41
0300-8428
http://hdl.handle.net/20.500.12105/5214
27164905
10.1007/s00395-016-0558-1
1435-1803
Basic Research in Cardiology
In the 30 years since the original description of ischaemic preconditioning, understanding of the pathophysiology of ischaemia/reperfusion injury and concepts of cardioprotection have been revolutionised. In the same period of time, management of patients with coronary artery disease has also been transformed: coronary artery and valve surgery are now deemed routine with generally excellent outcomes, and the management of acute coronary syndromes has seen decade on decade reductions in cardiovascular mortality. Nonetheless, despite these improvements, cardiovascular disease and ischaemic heart disease in particular, remain the leading cause of death and a significant cause of long-term morbidity (with a concomitant increase in the incidence of heart failure) worldwide. The need for effective cardioprotective strategies has never been so pressing. However, despite unequivocal evidence of the existence of ischaemia/reperfusion in animal models providing a robust rationale for study in man, recent phase 3 clinical trials studying a variety of cardioprotective strategies in cardiac surgery and acute ST-elevation myocardial infarction have provided mixed results. The investigators meeting at the Hatter Cardiovascular Institute workshop describe the challenge of translating strong pre-clinical data into effective clinical intervention strategies in patients in whom effective medical therapy is already altering the pathophysiology of ischaemia/reperfusion injury-and lay out a clearly defined framework for future basic and clinical research to improve the chances of successful translation of strong pre-clinical interventions in man.
eng
Ischaemia
Reperfusion
Injury
Infarction
Pre-clinical
Basic research
Clinical trials
Ischaemic
Preconditioning
Postconditioning
Conditioning
RISK pathway
SAFE pathway
p2y12
Opiates
Asprin
Beta blockers
Statins
Metoprolol
Cyclosporine
CABG
Valve replacement
Cardiac surgery
Mitochondrial transition pore
Necrosis
Apoptosis
Necroptosis
Autophagy
Pyroptosis
DNA
ACUTE MYOCARDIAL-INFARCTION
PERCUTANEOUS CORONARY INTERVENTION
ISCHEMIA-REPERFUSION INJURY
MITOCHONDRIAL PERMEABILITY TRANSITION
BYPASS GRAFT-SURGERY
CYCLOSPORINE-A
SIGNAL-TRANSDUCTION
EXPERIMENTAL-MODELS
CARDIAC-SURGERY
SALVAGE KINASE
9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection
journal article
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5214/1/9thHatterBiannualMeeting_2016
File
MD5
97c2dda353e1b47d3af551df5607f7e1
917078
application/pdf
9thHatterBiannualMeeting_2016
URL
https://repisalud.isciii.es/bitstream/20.500.12105/5214/10/9thHatterBiannualMeeting_2016.txt
File
MD5
0bfeb529db2e5579122b359c64f621dc
69178
text/plain
9thHatterBiannualMeeting_2016.txt